Global Second-Generation Antipsychotics Market Growth 2025-2031--LP INFORMATION, INC.

Global Second-Generation Antipsychotics Market Growth 2025-2031

Product Code: 1430871

Industry: Pharma & Healthcare

Published: Apr 05,2025

Pages: 145

Delivery Time: 2-3 business days

Global Second-Generation Antipsychotics Market Growth 2025-2031

Product Code: 1430871

Industry: Pharma & Healthcare

Published: Apr 05,2025

Pages: 145

Delivery Time: 2-3 business days

Select A Format

Single User License

USD3660

Multi Users License

USD5490

Corporate Users License

USD7320

Buy Now

Add To Cart

Or More Options：

PDF Download

Sample Request

Custom Request

Provide market analysis and obtain sources of data reports

Description

The global Second-Generation Antipsychotics market size is predicted to grow from US$ 44760 million in 2025 to US$ 49650 million in 2031; it is expected to grow at a CAGR of 1.7% from 2025 to 2031.

Second-generation antipsychotics, also known as atypical antipsychotics or novel antipsychotics. Compared with the first generation drugs, the second generation antipsychotic drugs have significant differences in pharmacological mechanisms, clinical efficacy, and side effect profiles, making them the mainstream choice for the treatment of severe mental disorders such as schizophrenia and bipolar disorder. From the perspective of pharmacological mechanisms, second-generation antipsychotics can be divided into four categories: 5-hydroxytryptamine and dopamine receptor antagonists (such as risperidone, olanzapine, quetiapine, and ziprasidone), multi receptor acting drugs (such as clozapine), selective dopamine receptor antagonists (such as amisulpride), and dopamine receptor partial agonists (such as aripiprazole).

The global market for second-generation antipsychotics has shown a growth trend in recent years. Core products such as olanzapine, quetiapine, and risperidone have long dominated sales, while relatively new drugs such as aripiprazole and ziprasidone have also shown good growth momentum. The main driving factors of the market include the increasing burden of mental illness, changes in treatment concepts, increased policy support, and breakthroughs in research and development innovation. The market has significant regional differences. Currently, North America holds the largest market share, with multinational pharmaceutical giants such as Pfizer, Eli Lilly, Novartis, and Merck dominating the market. The European market follows closely behind, with a slightly slower growth rate than North America, but the competitive landscape is more fragmented with numerous participants. In the Asia Pacific region, the Japanese market is relatively small and growing slowly, dominated by several large local pharmaceutical companies. The Chinese and Indian markets are not large in scale, but their growth rates are significantly higher than the global average, making them key regions for global pharmaceutical companies to layout. In the future, market differentiation will intensify, and original drugs with expired patents will face fierce competition from generic drugs, resulting in a significant decrease in prices, while new mechanism drugs with significant clinical advantages can gain premium space. Early intervention for mental illness will receive more attention, and the demand for low-dose formulations and drugs with fewer side effects suitable for early intervention will increase. Digital health technologies such as electronic prescriptions, telemedicine, and medication compliance monitoring will be deeply integrated with antipsychotic drug treatment. Emerging economies such as China and India will become important engines of global growth. With the improvement of medical infrastructure and increased payment capacity, the demand for high-quality antipsychotic drugs will rapidly grow, providing strategic opportunities for global pharmaceutical companies.

LP Information, Inc. (LPI) ' newest research report, the “Second-Generation Antipsychotics Industry Forecast” looks at past sales and reviews total world Second-Generation Antipsychotics sales in 2024, providing a comprehensive analysis by region and market sector of projected Second-Generation Antipsychotics sales for 2025 through 2031. With Second-Generation Antipsychotics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Second-Generation Antipsychotics industry.

This Insight Report provides a comprehensive analysis of the global Second-Generation Antipsychotics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Second-Generation Antipsychotics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Second-Generation Antipsychotics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Second-Generation Antipsychotics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Second-Generation Antipsychotics.

This report presents a comprehensive overview, market shares, and growth opportunities of Second-Generation Antipsychotics market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    5-Hydroxytryptamine And Dopamine Receptor Antagonists

    Multi Receptor Acting Drugs

    Selective Dopamine Receptor Antagonists

    Dopamine Receptor Partial Agonists

Segmentation by Application:

    Schizophrenia

    Bipolar Disorder

    Adjuvant Treatment For Depression

    Other Mental Illnesses

This report also splits the market by region:

    Americas

    United States

    Canada

    Mexico

    Brazil

    APAC

    China

    Japan

    Korea

    Southeast Asia

    India

    Australia

    Europe

    Germany

    France

UK

    Italy

    Russia

    Middle East & Africa

    Egypt

    South Africa

    Israel

    Turkey

    GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

    Sumitomo Dainippon Pharma

    Roche

    Pfizer

    Novartis

    Otsuka Pharmaceutical

    AbbVie

    Johnson And Johnson

    Ipsen

    Merck

    Eli Lilly

    Luye Pharma Group

    Nhwa Pharmaceutical

    Livzon Pharmaceutical Group

    Qilu Pharmaceutical

    CSPC Pharmaceutical Group

    Chengdu Kanghong Pharmaceutical

    Hansoh Pharma

    Hisun Pharmaceutical

    Chia Tai Tianqing Pharmaceutical

    Yangtze River Pharmaceutical Group

Key Questions Addressed in this Report

What is the 10-year outlook for the global Second-Generation Antipsychotics market?

What factors are driving Second-Generation Antipsychotics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Second-Generation Antipsychotics market opportunities vary by end market size?

How does Second-Generation Antipsychotics break out by Type, by Application?

Table Of Contents

1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
    1.8 Market Estimation Caveats

2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Second-Generation Antipsychotics Annual Sales 2020-2031
        2.1.2 World Current & Future Analysis for Second-Generation Antipsychotics by Geographic Region, 2020, 2024 & 2031
        2.1.3 World Current & Future Analysis for Second-Generation Antipsychotics by Country/Region, 2020, 2024 & 2031
    2.2 Second-Generation Antipsychotics Segment by Type
        2.2.1 5-Hydroxytryptamine And Dopamine Receptor Antagonists
        2.2.2 Multi Receptor Acting Drugs
        2.2.3 Selective Dopamine Receptor Antagonists
        2.2.4 Dopamine Receptor Partial Agonists
    2.3 Second-Generation Antipsychotics Sales by Type
        2.3.1 Global Second-Generation Antipsychotics Sales Market Share by Type (2020-2025)
        2.3.2 Global Second-Generation Antipsychotics Revenue and Market Share by Type (2020-2025)
        2.3.3 Global Second-Generation Antipsychotics Sale Price by Type (2020-2025)
    2.4 Second-Generation Antipsychotics Segment by Application
        2.4.1 Schizophrenia
        2.4.2 Bipolar Disorder
        2.4.3 Adjuvant Treatment For Depression
        2.4.4 Other Mental Illnesses
    2.5 Second-Generation Antipsychotics Sales by Application
        2.5.1 Global Second-Generation Antipsychotics Sale Market Share by Application (2020-2025)
        2.5.2 Global Second-Generation Antipsychotics Revenue and Market Share by Application (2020-2025)
        2.5.3 Global Second-Generation Antipsychotics Sale Price by Application (2020-2025)

3 Global by Company
    3.1 Global Second-Generation Antipsychotics Breakdown Data by Company
        3.1.1 Global Second-Generation Antipsychotics Annual Sales by Company (2020-2025)
        3.1.2 Global Second-Generation Antipsychotics Sales Market Share by Company (2020-2025)
    3.2 Global Second-Generation Antipsychotics Annual Revenue by Company (2020-2025)
        3.2.1 Global Second-Generation Antipsychotics Revenue by Company (2020-2025)
        3.2.2 Global Second-Generation Antipsychotics Revenue Market Share by Company (2020-2025)
    3.3 Global Second-Generation Antipsychotics Sale Price by Company
    3.4 Key Manufacturers Second-Generation Antipsychotics Producing Area Distribution, Sales Area, Product Type
        3.4.1 Key Manufacturers Second-Generation Antipsychotics Product Location Distribution
        3.4.2 Players Second-Generation Antipsychotics Products Offered
    3.5 Market Concentration Rate Analysis
        3.5.1 Competition Landscape Analysis
        3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
    3.6 New Products and Potential Entrants
    3.7 Market M&A Activity & Strategy

4 World Historic Review for Second-Generation Antipsychotics by Geographic Region
    4.1 World Historic Second-Generation Antipsychotics Market Size by Geographic Region (2020-2025)
        4.1.1 Global Second-Generation Antipsychotics Annual Sales by Geographic Region (2020-2025)
        4.1.2 Global Second-Generation Antipsychotics Annual Revenue by Geographic Region (2020-2025)
    4.2 World Historic Second-Generation Antipsychotics Market Size by Country/Region (2020-2025)
        4.2.1 Global Second-Generation Antipsychotics Annual Sales by Country/Region (2020-2025)
        4.2.2 Global Second-Generation Antipsychotics Annual Revenue by Country/Region (2020-2025)
    4.3 Americas Second-Generation Antipsychotics Sales Growth
    4.4 APAC Second-Generation Antipsychotics Sales Growth
    4.5 Europe Second-Generation Antipsychotics Sales Growth
    4.6 Middle East & Africa Second-Generation Antipsychotics Sales Growth

5 Americas
    5.1 Americas Second-Generation Antipsychotics Sales by Country
        5.1.1 Americas Second-Generation Antipsychotics Sales by Country (2020-2025)
        5.1.2 Americas Second-Generation Antipsychotics Revenue by Country (2020-2025)
    5.2 Americas Second-Generation Antipsychotics Sales by Type (2020-2025)
    5.3 Americas Second-Generation Antipsychotics Sales by Application (2020-2025)
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil

6 APAC
    6.1 APAC Second-Generation Antipsychotics Sales by Region
        6.1.1 APAC Second-Generation Antipsychotics Sales by Region (2020-2025)
        6.1.2 APAC Second-Generation Antipsychotics Revenue by Region (2020-2025)
    6.2 APAC Second-Generation Antipsychotics Sales by Type (2020-2025)
    6.3 APAC Second-Generation Antipsychotics Sales by Application (2020-2025)
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia
    6.10 China Taiwan

7 Europe
    7.1 Europe Second-Generation Antipsychotics by Country
        7.1.1 Europe Second-Generation Antipsychotics Sales by Country (2020-2025)
        7.1.2 Europe Second-Generation Antipsychotics Revenue by Country (2020-2025)
    7.2 Europe Second-Generation Antipsychotics Sales by Type (2020-2025)
    7.3 Europe Second-Generation Antipsychotics Sales by Application (2020-2025)
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia

8 Middle East & Africa
    8.1 Middle East & Africa Second-Generation Antipsychotics by Country
        8.1.1 Middle East & Africa Second-Generation Antipsychotics Sales by Country (2020-2025)
        8.1.2 Middle East & Africa Second-Generation Antipsychotics Revenue by Country (2020-2025)
    8.2 Middle East & Africa Second-Generation Antipsychotics Sales by Type (2020-2025)
    8.3 Middle East & Africa Second-Generation Antipsychotics Sales by Application (2020-2025)
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries

9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends

10 Manufacturing Cost Structure Analysis
    10.1 Raw Material and Suppliers
    10.2 Manufacturing Cost Structure Analysis of Second-Generation Antipsychotics
    10.3 Manufacturing Process Analysis of Second-Generation Antipsychotics
    10.4 Industry Chain Structure of Second-Generation Antipsychotics

11 Marketing, Distributors and Customer
    11.1 Sales Channel
        11.1.1 Direct Channels
        11.1.2 Indirect Channels
    11.2 Second-Generation Antipsychotics Distributors
    11.3 Second-Generation Antipsychotics Customer

12 World Forecast Review for Second-Generation Antipsychotics by Geographic Region
    12.1 Global Second-Generation Antipsychotics Market Size Forecast by Region
        12.1.1 Global Second-Generation Antipsychotics Forecast by Region (2026-2031)
        12.1.2 Global Second-Generation Antipsychotics Annual Revenue Forecast by Region (2026-2031)
    12.2 Americas Forecast by Country (2026-2031)
    12.3 APAC Forecast by Region (2026-2031)
    12.4 Europe Forecast by Country (2026-2031)
    12.5 Middle East & Africa Forecast by Country (2026-2031)
    12.6 Global Second-Generation Antipsychotics Forecast by Type (2026-2031)
    12.7 Global Second-Generation Antipsychotics Forecast by Application (2026-2031)

13 Key Players Analysis
    13.1 Sumitomo Dainippon Pharma
        13.1.1 Sumitomo Dainippon Pharma Company Information
        13.1.2 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolios and Specifications
        13.1.3 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.1.4 Sumitomo Dainippon Pharma Main Business Overview
        13.1.5 Sumitomo Dainippon Pharma Latest Developments
    13.2 Roche
        13.2.1 Roche Company Information
        13.2.2 Roche Second-Generation Antipsychotics Product Portfolios and Specifications
        13.2.3 Roche Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.2.4 Roche Main Business Overview
        13.2.5 Roche Latest Developments
    13.3 Pfizer
        13.3.1 Pfizer Company Information
        13.3.2 Pfizer Second-Generation Antipsychotics Product Portfolios and Specifications
        13.3.3 Pfizer Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.3.4 Pfizer Main Business Overview
        13.3.5 Pfizer Latest Developments
    13.4 Novartis
        13.4.1 Novartis Company Information
        13.4.2 Novartis Second-Generation Antipsychotics Product Portfolios and Specifications
        13.4.3 Novartis Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.4.4 Novartis Main Business Overview
        13.4.5 Novartis Latest Developments
    13.5 Otsuka Pharmaceutical
        13.5.1 Otsuka Pharmaceutical Company Information
        13.5.2 Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
        13.5.3 Otsuka Pharmaceutical Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.5.4 Otsuka Pharmaceutical Main Business Overview
        13.5.5 Otsuka Pharmaceutical Latest Developments
    13.6 AbbVie
        13.6.1 AbbVie Company Information
        13.6.2 AbbVie Second-Generation Antipsychotics Product Portfolios and Specifications
        13.6.3 AbbVie Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.6.4 AbbVie Main Business Overview
        13.6.5 AbbVie Latest Developments
    13.7 Johnson And Johnson
        13.7.1 Johnson And Johnson Company Information
        13.7.2 Johnson And Johnson Second-Generation Antipsychotics Product Portfolios and Specifications
        13.7.3 Johnson And Johnson Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.7.4 Johnson And Johnson Main Business Overview
        13.7.5 Johnson And Johnson Latest Developments
    13.8 Ipsen
        13.8.1 Ipsen Company Information
        13.8.2 Ipsen Second-Generation Antipsychotics Product Portfolios and Specifications
        13.8.3 Ipsen Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.8.4 Ipsen Main Business Overview
        13.8.5 Ipsen Latest Developments
    13.9 Merck
        13.9.1 Merck Company Information
        13.9.2 Merck Second-Generation Antipsychotics Product Portfolios and Specifications
        13.9.3 Merck Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.9.4 Merck Main Business Overview
        13.9.5 Merck Latest Developments
    13.10 Eli Lilly
        13.10.1 Eli Lilly Company Information
        13.10.2 Eli Lilly Second-Generation Antipsychotics Product Portfolios and Specifications
        13.10.3 Eli Lilly Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.10.4 Eli Lilly Main Business Overview
        13.10.5 Eli Lilly Latest Developments
    13.11 Luye Pharma Group
        13.11.1 Luye Pharma Group Company Information
        13.11.2 Luye Pharma Group Second-Generation Antipsychotics Product Portfolios and Specifications
        13.11.3 Luye Pharma Group Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.11.4 Luye Pharma Group Main Business Overview
        13.11.5 Luye Pharma Group Latest Developments
    13.12 Nhwa Pharmaceutical
        13.12.1 Nhwa Pharmaceutical Company Information
        13.12.2 Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
        13.12.3 Nhwa Pharmaceutical Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.12.4 Nhwa Pharmaceutical Main Business Overview
        13.12.5 Nhwa Pharmaceutical Latest Developments
    13.13 Livzon Pharmaceutical Group
        13.13.1 Livzon Pharmaceutical Group Company Information
        13.13.2 Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolios and Specifications
        13.13.3 Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.13.4 Livzon Pharmaceutical Group Main Business Overview
        13.13.5 Livzon Pharmaceutical Group Latest Developments
    13.14 Qilu Pharmaceutical
        13.14.1 Qilu Pharmaceutical Company Information
        13.14.2 Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
        13.14.3 Qilu Pharmaceutical Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.14.4 Qilu Pharmaceutical Main Business Overview
        13.14.5 Qilu Pharmaceutical Latest Developments
    13.15 CSPC Pharmaceutical Group
        13.15.1 CSPC Pharmaceutical Group Company Information
        13.15.2 CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolios and Specifications
        13.15.3 CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.15.4 CSPC Pharmaceutical Group Main Business Overview
        13.15.5 CSPC Pharmaceutical Group Latest Developments
    13.16 Chengdu Kanghong Pharmaceutical
        13.16.1 Chengdu Kanghong Pharmaceutical Company Information
        13.16.2 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
        13.16.3 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.16.4 Chengdu Kanghong Pharmaceutical Main Business Overview
        13.16.5 Chengdu Kanghong Pharmaceutical Latest Developments
    13.17 Hansoh Pharma
        13.17.1 Hansoh Pharma Company Information
        13.17.2 Hansoh Pharma Second-Generation Antipsychotics Product Portfolios and Specifications
        13.17.3 Hansoh Pharma Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.17.4 Hansoh Pharma Main Business Overview
        13.17.5 Hansoh Pharma Latest Developments
    13.18 Hisun Pharmaceutical
        13.18.1 Hisun Pharmaceutical Company Information
        13.18.2 Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
        13.18.3 Hisun Pharmaceutical Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.18.4 Hisun Pharmaceutical Main Business Overview
        13.18.5 Hisun Pharmaceutical Latest Developments
    13.19 Chia Tai Tianqing Pharmaceutical
        13.19.1 Chia Tai Tianqing Pharmaceutical Company Information
        13.19.2 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
        13.19.3 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.19.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
        13.19.5 Chia Tai Tianqing Pharmaceutical Latest Developments
    13.20 Yangtze River Pharmaceutical Group
        13.20.1 Yangtze River Pharmaceutical Group Company Information
        13.20.2 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolios and Specifications
        13.20.3 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue, Price and Gross Margin (2020-2025)
        13.20.4 Yangtze River Pharmaceutical Group Main Business Overview
        13.20.5 Yangtze River Pharmaceutical Group Latest Developments

14 Research Findings and Conclusion

List Of Tables

List of Tables
 Table 1. Second-Generation Antipsychotics Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
 Table 2. Second-Generation Antipsychotics Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
 Table 3. Major Players of 5-Hydroxytryptamine And Dopamine Receptor Antagonists
 Table 4. Major Players of Multi Receptor Acting Drugs
 Table 5. Major Players of Selective Dopamine Receptor Antagonists
 Table 6. Major Players of Dopamine Receptor Partial Agonists
 Table 7. Global Second-Generation Antipsychotics Sales by Type (2020-2025) & (Units)
 Table 8. Global Second-Generation Antipsychotics Sales Market Share by Type (2020-2025)
 Table 9. Global Second-Generation Antipsychotics Revenue by Type (2020-2025) & ($ million)
 Table 10. Global Second-Generation Antipsychotics Revenue Market Share by Type (2020-2025)
 Table 11. Global Second-Generation Antipsychotics Sale Price by Type (2020-2025) & (US$/Unit)
 Table 12. Global Second-Generation Antipsychotics Sale by Application (2020-2025) & (Units)
 Table 13. Global Second-Generation Antipsychotics Sale Market Share by Application (2020-2025)
 Table 14. Global Second-Generation Antipsychotics Revenue by Application (2020-2025) & ($ million)
 Table 15. Global Second-Generation Antipsychotics Revenue Market Share by Application (2020-2025)
 Table 16. Global Second-Generation Antipsychotics Sale Price by Application (2020-2025) & (US$/Unit)
 Table 17. Global Second-Generation Antipsychotics Sales by Company (2020-2025) & (Units)
 Table 18. Global Second-Generation Antipsychotics Sales Market Share by Company (2020-2025)
 Table 19. Global Second-Generation Antipsychotics Revenue by Company (2020-2025) & ($ millions)
 Table 20. Global Second-Generation Antipsychotics Revenue Market Share by Company (2020-2025)
 Table 21. Global Second-Generation Antipsychotics Sale Price by Company (2020-2025) & (US$/Unit)
 Table 22. Key Manufacturers Second-Generation Antipsychotics Producing Area Distribution and Sales Area
 Table 23. Players Second-Generation Antipsychotics Products Offered
 Table 24. Second-Generation Antipsychotics Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
 Table 25. New Products and Potential Entrants
 Table 26. Market M&A Activity & Strategy
 Table 27. Global Second-Generation Antipsychotics Sales by Geographic Region (2020-2025) & (Units)
 Table 28. Global Second-Generation Antipsychotics Sales Market Share Geographic Region (2020-2025)
 Table 29. Global Second-Generation Antipsychotics Revenue by Geographic Region (2020-2025) & ($ millions)
 Table 30. Global Second-Generation Antipsychotics Revenue Market Share by Geographic Region (2020-2025)
 Table 31. Global Second-Generation Antipsychotics Sales by Country/Region (2020-2025) & (Units)
 Table 32. Global Second-Generation Antipsychotics Sales Market Share by Country/Region (2020-2025)
 Table 33. Global Second-Generation Antipsychotics Revenue by Country/Region (2020-2025) & ($ millions)
 Table 34. Global Second-Generation Antipsychotics Revenue Market Share by Country/Region (2020-2025)
 Table 35. Americas Second-Generation Antipsychotics Sales by Country (2020-2025) & (Units)
 Table 36. Americas Second-Generation Antipsychotics Sales Market Share by Country (2020-2025)
 Table 37. Americas Second-Generation Antipsychotics Revenue by Country (2020-2025) & ($ millions)
 Table 38. Americas Second-Generation Antipsychotics Sales by Type (2020-2025) & (Units)
 Table 39. Americas Second-Generation Antipsychotics Sales by Application (2020-2025) & (Units)
 Table 40. APAC Second-Generation Antipsychotics Sales by Region (2020-2025) & (Units)
 Table 41. APAC Second-Generation Antipsychotics Sales Market Share by Region (2020-2025)
 Table 42. APAC Second-Generation Antipsychotics Revenue by Region (2020-2025) & ($ millions)
 Table 43. APAC Second-Generation Antipsychotics Sales by Type (2020-2025) & (Units)
 Table 44. APAC Second-Generation Antipsychotics Sales by Application (2020-2025) & (Units)
 Table 45. Europe Second-Generation Antipsychotics Sales by Country (2020-2025) & (Units)
 Table 46. Europe Second-Generation Antipsychotics Revenue by Country (2020-2025) & ($ millions)
 Table 47. Europe Second-Generation Antipsychotics Sales by Type (2020-2025) & (Units)
 Table 48. Europe Second-Generation Antipsychotics Sales by Application (2020-2025) & (Units)
 Table 49. Middle East & Africa Second-Generation Antipsychotics Sales by Country (2020-2025) & (Units)
 Table 50. Middle East & Africa Second-Generation Antipsychotics Revenue Market Share by Country (2020-2025)
 Table 51. Middle East & Africa Second-Generation Antipsychotics Sales by Type (2020-2025) & (Units)
 Table 52. Middle East & Africa Second-Generation Antipsychotics Sales by Application (2020-2025) & (Units)
 Table 53. Key Market Drivers & Growth Opportunities of Second-Generation Antipsychotics
 Table 54. Key Market Challenges & Risks of Second-Generation Antipsychotics
 Table 55. Key Industry Trends of Second-Generation Antipsychotics
 Table 56. Second-Generation Antipsychotics Raw Material
 Table 57. Key Suppliers of Raw Materials
 Table 58. Second-Generation Antipsychotics Distributors List
 Table 59. Second-Generation Antipsychotics Customer List
 Table 60. Global Second-Generation Antipsychotics Sales Forecast by Region (2026-2031) & (Units)
 Table 61. Global Second-Generation Antipsychotics Revenue Forecast by Region (2026-2031) & ($ millions)
 Table 62. Americas Second-Generation Antipsychotics Sales Forecast by Country (2026-2031) & (Units)
 Table 63. Americas Second-Generation Antipsychotics Annual Revenue Forecast by Country (2026-2031) & ($ millions)
 Table 64. APAC Second-Generation Antipsychotics Sales Forecast by Region (2026-2031) & (Units)
 Table 65. APAC Second-Generation Antipsychotics Annual Revenue Forecast by Region (2026-2031) & ($ millions)
 Table 66. Europe Second-Generation Antipsychotics Sales Forecast by Country (2026-2031) & (Units)
 Table 67. Europe Second-Generation Antipsychotics Revenue Forecast by Country (2026-2031) & ($ millions)
 Table 68. Middle East & Africa Second-Generation Antipsychotics Sales Forecast by Country (2026-2031) & (Units)
 Table 69. Middle East & Africa Second-Generation Antipsychotics Revenue Forecast by Country (2026-2031) & ($ millions)
 Table 70. Global Second-Generation Antipsychotics Sales Forecast by Type (2026-2031) & (Units)
 Table 71. Global Second-Generation Antipsychotics Revenue Forecast by Type (2026-2031) & ($ millions)
 Table 72. Global Second-Generation Antipsychotics Sales Forecast by Application (2026-2031) & (Units)
 Table 73. Global Second-Generation Antipsychotics Revenue Forecast by Application (2026-2031) & ($ millions)
 Table 74. Sumitomo Dainippon Pharma Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 75. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 76. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 77. Sumitomo Dainippon Pharma Main Business
 Table 78. Sumitomo Dainippon Pharma Latest Developments
 Table 79. Roche Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 80. Roche Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 81. Roche Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 82. Roche Main Business
 Table 83. Roche Latest Developments
 Table 84. Pfizer Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 85. Pfizer Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 86. Pfizer Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 87. Pfizer Main Business
 Table 88. Pfizer Latest Developments
 Table 89. Novartis Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 90. Novartis Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 91. Novartis Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 92. Novartis Main Business
 Table 93. Novartis Latest Developments
 Table 94. Otsuka Pharmaceutical Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 95. Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 96. Otsuka Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 97. Otsuka Pharmaceutical Main Business
 Table 98. Otsuka Pharmaceutical Latest Developments
 Table 99. AbbVie Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 100. AbbVie Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 101. AbbVie Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 102. AbbVie Main Business
 Table 103. AbbVie Latest Developments
 Table 104. Johnson And Johnson Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 105. Johnson And Johnson Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 106. Johnson And Johnson Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 107. Johnson And Johnson Main Business
 Table 108. Johnson And Johnson Latest Developments
 Table 109. Ipsen Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 110. Ipsen Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 111. Ipsen Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 112. Ipsen Main Business
 Table 113. Ipsen Latest Developments
 Table 114. Merck Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 115. Merck Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 116. Merck Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 117. Merck Main Business
 Table 118. Merck Latest Developments
 Table 119. Eli Lilly Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 120. Eli Lilly Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 121. Eli Lilly Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 122. Eli Lilly Main Business
 Table 123. Eli Lilly Latest Developments
 Table 124. Luye Pharma Group Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 125. Luye Pharma Group Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 126. Luye Pharma Group Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 127. Luye Pharma Group Main Business
 Table 128. Luye Pharma Group Latest Developments
 Table 129. Nhwa Pharmaceutical Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 130. Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 131. Nhwa Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 132. Nhwa Pharmaceutical Main Business
 Table 133. Nhwa Pharmaceutical Latest Developments
 Table 134. Livzon Pharmaceutical Group Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 135. Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 136. Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 137. Livzon Pharmaceutical Group Main Business
 Table 138. Livzon Pharmaceutical Group Latest Developments
 Table 139. Qilu Pharmaceutical Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 140. Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 141. Qilu Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 142. Qilu Pharmaceutical Main Business
 Table 143. Qilu Pharmaceutical Latest Developments
 Table 144. CSPC Pharmaceutical Group Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 145. CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 146. CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 147. CSPC Pharmaceutical Group Main Business
 Table 148. CSPC Pharmaceutical Group Latest Developments
 Table 149. Chengdu Kanghong Pharmaceutical Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 150. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 151. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 152. Chengdu Kanghong Pharmaceutical Main Business
 Table 153. Chengdu Kanghong Pharmaceutical Latest Developments
 Table 154. Hansoh Pharma Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 155. Hansoh Pharma Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 156. Hansoh Pharma Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 157. Hansoh Pharma Main Business
 Table 158. Hansoh Pharma Latest Developments
 Table 159. Hisun Pharmaceutical Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 160. Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 161. Hisun Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 162. Hisun Pharmaceutical Main Business
 Table 163. Hisun Pharmaceutical Latest Developments
 Table 164. Chia Tai Tianqing Pharmaceutical Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 165. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 166. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 167. Chia Tai Tianqing Pharmaceutical Main Business
 Table 168. Chia Tai Tianqing Pharmaceutical Latest Developments
 Table 169. Yangtze River Pharmaceutical Group Basic Information, Second-Generation Antipsychotics Manufacturing Base, Sales Area and Its Competitors
 Table 170. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolios and Specifications
 Table 171. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 172. Yangtze River Pharmaceutical Group Main Business
 Table 173. Yangtze River Pharmaceutical Group Latest Developments


List of Figures
 Figure 1. Picture of Second-Generation Antipsychotics
 Figure 2. Second-Generation Antipsychotics Report Years Considered
 Figure 3. Research Objectives
 Figure 4. Research Methodology
 Figure 5. Research Process and Data Source
 Figure 6. Global Second-Generation Antipsychotics Sales Growth Rate 2020-2031 (Units)
 Figure 7. Global Second-Generation Antipsychotics Revenue Growth Rate 2020-2031 ($ millions)
 Figure 8. Second-Generation Antipsychotics Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
 Figure 9. Second-Generation Antipsychotics Sales Market Share by Country/Region (2024)
 Figure 10. Second-Generation Antipsychotics Sales Market Share by Country/Region (2020, 2024 & 2031)
 Figure 11. Product Picture of 5-Hydroxytryptamine And Dopamine Receptor Antagonists
 Figure 12. Product Picture of Multi Receptor Acting Drugs
 Figure 13. Product Picture of Selective Dopamine Receptor Antagonists
 Figure 14. Product Picture of Dopamine Receptor Partial Agonists
 Figure 15. Global Second-Generation Antipsychotics Sales Market Share by Type in 2025
 Figure 16. Global Second-Generation Antipsychotics Revenue Market Share by Type (2020-2025)
 Figure 17. Second-Generation Antipsychotics Consumed in Schizophrenia
 Figure 18. Global Second-Generation Antipsychotics Market: Schizophrenia (2020-2025) & (Units)
 Figure 19. Second-Generation Antipsychotics Consumed in Bipolar Disorder
 Figure 20. Global Second-Generation Antipsychotics Market: Bipolar Disorder (2020-2025) & (Units)
 Figure 21. Second-Generation Antipsychotics Consumed in Adjuvant Treatment For Depression
 Figure 22. Global Second-Generation Antipsychotics Market: Adjuvant Treatment For Depression (2020-2025) & (Units)
 Figure 23. Second-Generation Antipsychotics Consumed in Other Mental Illnesses
 Figure 24. Global Second-Generation Antipsychotics Market: Other Mental Illnesses (2020-2025) & (Units)
 Figure 25. Global Second-Generation Antipsychotics Sale Market Share by Application (2024)
 Figure 26. Global Second-Generation Antipsychotics Revenue Market Share by Application in 2025
 Figure 27. Second-Generation Antipsychotics Sales by Company in 2025 (Units)
 Figure 28. Global Second-Generation Antipsychotics Sales Market Share by Company in 2025
 Figure 29. Second-Generation Antipsychotics Revenue by Company in 2025 ($ millions)
 Figure 30. Global Second-Generation Antipsychotics Revenue Market Share by Company in 2025
 Figure 31. Global Second-Generation Antipsychotics Sales Market Share by Geographic Region (2020-2025)
 Figure 32. Global Second-Generation Antipsychotics Revenue Market Share by Geographic Region in 2025
 Figure 33. Americas Second-Generation Antipsychotics Sales 2020-2025 (Units)
 Figure 34. Americas Second-Generation Antipsychotics Revenue 2020-2025 ($ millions)
 Figure 35. APAC Second-Generation Antipsychotics Sales 2020-2025 (Units)
 Figure 36. APAC Second-Generation Antipsychotics Revenue 2020-2025 ($ millions)
 Figure 37. Europe Second-Generation Antipsychotics Sales 2020-2025 (Units)
 Figure 38. Europe Second-Generation Antipsychotics Revenue 2020-2025 ($ millions)
 Figure 39. Middle East & Africa Second-Generation Antipsychotics Sales 2020-2025 (Units)
 Figure 40. Middle East & Africa Second-Generation Antipsychotics Revenue 2020-2025 ($ millions)
 Figure 41. Americas Second-Generation Antipsychotics Sales Market Share by Country in 2025
 Figure 42. Americas Second-Generation Antipsychotics Revenue Market Share by Country (2020-2025)
 Figure 43. Americas Second-Generation Antipsychotics Sales Market Share by Type (2020-2025)
 Figure 44. Americas Second-Generation Antipsychotics Sales Market Share by Application (2020-2025)
 Figure 45. United States Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 46. Canada Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 47. Mexico Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 48. Brazil Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 49. APAC Second-Generation Antipsychotics Sales Market Share by Region in 2025
 Figure 50. APAC Second-Generation Antipsychotics Revenue Market Share by Region (2020-2025)
 Figure 51. APAC Second-Generation Antipsychotics Sales Market Share by Type (2020-2025)
 Figure 52. APAC Second-Generation Antipsychotics Sales Market Share by Application (2020-2025)
 Figure 53. China Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 54. Japan Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 55. South Korea Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 56. Southeast Asia Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 57. India Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 58. Australia Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 59. China Taiwan Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 60. Europe Second-Generation Antipsychotics Sales Market Share by Country in 2025
 Figure 61. Europe Second-Generation Antipsychotics Revenue Market Share by Country (2020-2025)
 Figure 62. Europe Second-Generation Antipsychotics Sales Market Share by Type (2020-2025)
 Figure 63. Europe Second-Generation Antipsychotics Sales Market Share by Application (2020-2025)
 Figure 64. Germany Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 65. France Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 66. UK Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 67. Italy Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 68. Russia Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 69. Middle East & Africa Second-Generation Antipsychotics Sales Market Share by Country (2020-2025)
 Figure 70. Middle East & Africa Second-Generation Antipsychotics Sales Market Share by Type (2020-2025)
 Figure 71. Middle East & Africa Second-Generation Antipsychotics Sales Market Share by Application (2020-2025)
 Figure 72. Egypt Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 73. South Africa Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 74. Israel Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 75. Turkey Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 76. GCC Countries Second-Generation Antipsychotics Revenue Growth 2020-2025 ($ millions)
 Figure 77. Manufacturing Cost Structure Analysis of Second-Generation Antipsychotics in 2025
 Figure 78. Manufacturing Process Analysis of Second-Generation Antipsychotics
 Figure 79. Industry Chain Structure of Second-Generation Antipsychotics
 Figure 80. Channels of Distribution
 Figure 81. Global Second-Generation Antipsychotics Sales Market Forecast by Region (2026-2031)
 Figure 82. Global Second-Generation Antipsychotics Revenue Market Share Forecast by Region (2026-2031)
 Figure 83. Global Second-Generation Antipsychotics Sales Market Share Forecast by Type (2026-2031)
 Figure 84. Global Second-Generation Antipsychotics Revenue Market Share Forecast by Type (2026-2031)
 Figure 85. Global Second-Generation Antipsychotics Sales Market Share Forecast by Application (2026-2031)
 Figure 86. Global Second-Generation Antipsychotics Revenue Market Share Forecast by Application (2026-2031)

Companies Mentioned

Sumitomo Dainippon Pharma

Roche

Pfizer

Novartis

Otsuka Pharmaceutical

AbbVie

Johnson And Johnson

Ipsen

Merck

Eli Lilly

Luye Pharma Group

Nhwa Pharmaceutical

Livzon Pharmaceutical Group

Qilu Pharmaceutical

CSPC Pharmaceutical Group

Chengdu Kanghong Pharmaceutical

Hansoh Pharma

Hisun Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Yangtze River Pharmaceutical Group

Methodology

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

Data Sourse

Primary Source

Secondary Source

Players/Suppliers

Journals and Periodicals

Industry Experts

Government Bodies

Distributors/Traders

Annual Reports

Opinion Leaders

Presentations

Front-line Staff